Boehringer Ingelheim Corporation, a leading global pharmaceutical company, is headquartered in the United States and operates extensively across Europe, Asia, and other regions. Founded in 1885, the company has established itself as a key player in the pharmaceutical and animal health industries, focusing on innovative research and development. Boehringer Ingelheim is renowned for its core products, which include prescription medications, vaccines, and animal health solutions. Their commitment to advancing healthcare through unique therapeutic approaches sets them apart in a competitive market. With a strong emphasis on human and veterinary medicine, the company has achieved notable milestones, including significant advancements in respiratory and cardiovascular treatments. As a prominent entity in the pharmaceutical landscape, Boehringer Ingelheim continues to enhance its market position through a dedication to innovation and sustainability, making a lasting impact on global health.
How does Boehringer Ingelheim Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Corporation's score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Corporation, headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of C.H. Boehringer Sohn AG & Co. KG, which may influence its climate commitments and performance metrics. Despite the lack of specific emissions data, Boehringer Ingelheim Corporation is part of a broader corporate family that may have established climate initiatives. However, no specific reduction targets or commitments have been documented for the corporation itself. The absence of data on initiatives such as Science Based Targets Initiative (SBTi) or other climate pledges suggests that the company may still be in the process of developing its climate strategy. As a subsidiary, Boehringer Ingelheim Corporation's climate actions may be aligned with those of its parent company, but specific details on emissions reductions or commitments are not available at this time. The company is expected to engage in ongoing efforts to address climate change, reflecting industry standards and practices.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

